SCB Genomic Revolution (Accumulation)

SCBGENOME(A)



Derivative -0.29% Other -1.88%

Deposit 5.47% ISHARES GENOMICS

IMMUNOLOGY AND



Date 31 March 2025

Fund Type

Fund Registration date

Investment Policy

Foreign Investment Fund

at least 2 foreign mutual funds that focus on investing in securities/instruments of companies related to the Genomic Revolution Theme, which focuses on and expected to benefit from quality development of human life through development and progress in technology and science, on average, in an accounting year of not less than 80% of the

Net Asset Value

Net Asset Value Per Unit

Policy on Dividend Payment

Automatic redemption policy

Risk Involved

Baht 55.25 million

Baht 2.4401

No Dividend Payment

No AutoRedeem

1. Leverage Risk

2. The risk of changes in the price or value of the underlying asset.

3. Call Risk

4. Liquidity Risk

5 Business Bisk

6. Country Risk

7. Repatriation Risk

8. Market Risk 9. Credit Risk

10. Exchange rate Risk

11. Reinvestment Risk

12. The risk of delay payment from foreign funds.

Discretionary hedged

Health Care

Fund Summary

20 August 2021

The Fund will invest in the investment unit of Fund's NAV.

Fund Performance vs Benchmark

ARK GENOMIC

REVOLUTION ETF 69.99%

Fund Performance	Return				Annualized Return						
	YTD	3 Mti	ns 6 M	/Iths	1 Yr	3 Yrs	5 Yrs	10 Y	'rs I	Since ception	
SCBGENOME(A)	-11.27%	-11.27	% -16	.55%	-27.47%	-25.25%	n.a.	n.a	. .	-32.30%	
Benchmark ¹	-2.65%	-2.659	% -7.	90%	-19.06%	-19.48%	n.a.	n.a		-28.13%	
Portfolio SD	19.97%	19.97	% 26.	14%	36.91%	43.64%	n.a.	n.a		44.50%	
Benchmark SD	6.81%	6.819	6 17.	11%	29.00%	41.01%	n.a.	n.a		42.56%	
Annual Return	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	

Annual Return	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
SCBGENOME(A)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	-22.03%	-54.51%	6.04%	-26.89%
Benchmark ¹	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	-21.35%	-54.13%	10.36%	-21.85%
Portfolio SD	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	39.97%	59.51%	36.92%	36.10%
Benchmark SD	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	40.19%	59.90%	35.68%	32.95%

Class Date 20 August 2021

Asset Allocation

FX hedging policy AIMC Category

Date & Time

Subscription / Redemption

Minimum Additional Subcription Amount

Minimum Redemption Minimum Balance

Redemption Settlement Date

Before 3.30 p.m. of every working day and before 4.00 p.m. for SCB Easy

Baht 1,000 / Baht 1,000

Baht 1,000 Baht 1 000

> 4 business days after the date of redemption (T+4)

Fund Details

	% Of NAV
Security	
1.ARK GENOMIC REVOLUTION ETF	69.99
2.ISHARES GENOMICS IMMUNOLOGY AND HEALTHCARE ETF	26.70
Industry	
1.UNIT TRUST	96.69

Master Fund

SCB Genomic Revolution (Accumulation) -- Master Fund Fact Sheet

AIMC Category Performance Report

	Average Trailing Return (%)							Average Calendar Year Return (9					
AIMC Category	YTD	3M	6M	1Y	3Y	5Y	10Y	2020	2021	2022	2023	2024	
Health Care	-0.06	-0.06	-9.70	-11.73	-6.95	5.11	2.88	22.59	7.71	-19.54	-0.96	-7.28	

Fees Collected from Unit holders

Front-end fee

Trustee Fee

Registrar Fee

Not exceed 3.21% of NAV (Currently charged at 1%)

Back-end fee Not exceed 3.21% of NAV (waived)

Switch In fee Not exceed 3.21% of NAV (Currently charged at 1%)

Switch Out fee Not exceed 3.21% of NAV (waived) **Brokerage Fee** Not exceed 0.75 % of NAV (waived)

(All Transaction)

Transfer fee Baht 10 per 1,000 units

Fees Collected from the Fund (included of VAT)(%p.a.of NAV)

Management Fee Not exceed 2.68 p.a. (Currently charged at 0.5%)

> Not exceed 0.11 p.a. (Currently charged at 0.0321%)

Not exceed 0.11 p.a.

(Currently charged at 0.06527%)

Other expenses Actual expense Not exceed 2.68%

¹Bloomberg Developed Markets Large & Mid Cap Net Return Index (USD) 100% adjusted with the FX hedging cost to calculate return into Thai Baht on investment date (50%) and adjusted with the exchange rate to compare with Thai Baht on return calculation date (50%) (Change of benchmark is effective from 1 January 2025 onwards.)



